Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 4,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ADM Clear all

Conditions: Hodgkin Lymphoma
Interventions: Rituximab, Involved field irradiation; Drug · Radiation
Lead sponsor: Fondazione Michelangelo; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stroke
Interventions: Group Lifestyle Balance, Usual Care; Behavioral · Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Lymphoma
Interventions: filgrastim, pegfilgrastim, rituximab, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, liposomal cytarabine, methotrexate, therapeutic hydrocortisone, vincristine sulfate; Biological · Drug
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years to 120 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 13
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 9 more

Conditions: Breast Cancer
Interventions: Intraductal arm, Intravenous arm; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: Indianapolis, Indiana • Baltimore, Maryland

Conditions: Endometriosis, Chronic Pelvic Pain
Interventions: ketamine; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 89 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: bortezomib, melphalan, pegylated liposomal doxorubicin hydrochloride; Drug
Lead sponsor: Herbert Irving Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: Lymphoma
Interventions: filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Not listed
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 47
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more

Conditions: Pseudotumor Cerebri, Idiopathic Intracranial Hypertension (IIH)
Interventions: Dural Venous Sinus Stenting, Cerebrospinal Fluid Shunting; Device
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Phoenix, Arizona • Seattle, Washington

Conditions: Cardiac Arrhythmia
Interventions: Oxytocin, Saline; Drug · Other
Lead sponsor: William Whang; Other
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Neoplasms
Interventions: Formal study using hyperpolarized 13C-pyruvate injection, Feasible study using hyperpolarized 13C-pyruvate injection; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Childhood Obesity Pevention, Diet Quality, Feeding Behaviors, Health Behavior Change, Rural Health
Interventions: EAT Family Style, Better Kid Care; Behavioral
Lead sponsor: University of Nebraska Lincoln; Other
Eligibility: 3 Years and older
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Sarcoma
Interventions: Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pembrolizumab; Drug · Other · Biological
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Caregiver Burden, Behavioral and Psychiatric Symptoms of Dementia, Depressive Symptoms, Quality of Life, Psychological Flexibility, Sleep Quality, Positive Aspects of Caregiving
Interventions: Acceptance and Commitment Therapy; Behavioral
Lead sponsor: Utah State University; Other
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Logan, Utah

Conditions: Anesthesia, Surgery, Hypotension
Interventions: Norepinephrine, Phenylephrine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 99 Years
Enrollment: 3,626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California

Conditions: Prostate Cancer
Interventions: pegylated liposomal doxorubicin hydrochloride, hyperthermia treatment; Drug · Procedure
Lead sponsor: Imunon; Industry
Eligibility: 40 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 2
States / cities: Shreveport, Louisiana • Myrtle Beach, South Carolina

Conditions: Anesthesia
Interventions: Pediatric SedLine forehead EEG sensor; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 12 Months to 17 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: Anger, Intermittent Explosive Disorder, Emotional Distress, Aggression, Violence
Interventions: Cognitive Behavioral Affective Therapy, Emotional Discussion; Behavioral
Lead sponsor: The University of Texas at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Mental Disorder, Physical Illness
Interventions: Integrated Care, Peer Navigation; Behavioral
Lead sponsor: Illinois Institute of Technology; Other
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Alzheimer Disease, Dementia, Gamification, Assistive Technology
Interventions: The MapHabit system (MHS); Device
Lead sponsor: MapHabit, Inc.; Industry
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Type 1 Diabetes Mellitus
Interventions: Afrezza; Biological
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 13
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 8 more

Conditions: Williams Syndrome, Lipedema
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma, Plasma Cell Myeloma
Interventions: bortezomib, cisplatin, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, etoposide, lenalidomide, melphalan, thalidomide, gene expression analysis, microarray analysis, laboratory biomarker analysis, autologous-autologous tandem hematopoietic stem cell transplantation; Drug · Genetic · Other + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 21
States / cities: Alexandria, Louisiana • Baton Rouge, Louisiana • Detroit, Michigan + 12 more

Conditions: Gestational Diabetes Mellitus in Pregnancy
Interventions: Diabetes Treatment, Usual Care Group; Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Miami, Florida • Decatur, Georgia + 5 more

Conditions: Lymphoma, Lymphoma, Large B-Cell, Diffuse
Interventions: Glofitamab, Polatuzumab, Rituximab, Doxorubicin Hydrochloride, Cyclophosphamide, Prednisone; Drug
Lead sponsor: Jennifer Crombie, MD; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Miami, Florida • Boston, Massachusetts

Search by objective public record fields.

R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma

Group Lifestyle Balance™ for Individuals With Stroke (GLB-CVA)

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer

Ketamine in Central Sensitization

Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

Operative Procedures Vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial

Oxytocin Effects on Cardiac Electrophysiology

Using Hyperpolarized [1-13C]Pyruvate to Detect Cardiotoxicity

Healthy Children, Healthy Communities: Effectiveness of a Multilevel Rural Community Engagement Model for Improving Children's Dietary Intake in Family Child Care Homes

Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery

Acceptance Commitment Therapy for Caregivers of People with Memory Loss

Norepinephrine vs Phenylephrine During General Anesthesia

Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer

SedLine Engineering Data Collection Study in Pediatric Patients Undergoing General Anesthesia or Sedation

Maladaptive Anger Treatment

Peer Navigators for the Health and Wellness of People With Psychiatric Disabilities

Efficacy of Gamification in Enhancing User Engagement

Afrezza Safety and Pharmacokinetics Study in Pediatric Patients

Williams Syndrome Strength, Hormones, Activity & Adiposity, DNA Programming, Eating Study

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

CGM for the Early Detection and Management of Hyperglycemia in Pregnancy

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma